Expression of PDL-1 between primary and recurrent/metastatic head and neck squamous cell carcinoma: A bi-institutional retrospective concordance analysis (CONCORDL-1 study)
-
Published:2024-10
Issue:
Volume:157
Page:106950
-
ISSN:1368-8375
-
Container-title:Oral Oncology
-
language:en
-
Short-container-title:Oral Oncology
Author:
Lorini L.ORCID,
Zigliani G.,
Morbini P.,
Salviato E.,
Piazza C.,
Battocchio S.,
Preda L.,
Benazzo M.,
Ravanelli M.,
Mattavelli D.,
Bossi P.
Reference26 articles.
1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021
2. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Machiels;Ann Oncol,2020
3. Nivolumab for recurrent squamous-cell carcinoma of the head and neck;Ferris;N Engl J Med,2016
4. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study;Cohen;Lancet,2019
5. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study;Burtness;Lancet,2019